LakeShore Biopharma (LSB) said Friday that it has been granted approval by China's National Medical Products Administration for a phase 3 clinical study of a simplified four-dose regimen for its YSJA rabies vaccine.
The biopharmaceutical company said the study will begin in December and will evaluate the immunogenicity and safety of its YSJA rabies vaccine across two four-dose immunization schedules compared with the existing five-dose Essen regimen.
Shares of LakeShore Biopharma were down more than 4% in early trading Friday.
Price: 3.0000, Change: -0.14, Percent Change: -4.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.